IP Verse

(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof

PatentPatent Analysis

EP2223688

AMGEN EUROPE
Application Number
EP10162667A
Filing Date
Mar 20, 2003
Status
Revoked
Jan 21, 2022
Grant Date
May 29, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2651400B2
EP3320902B1
EP2797581B1

Bibliography

The patent EP2223688B1 was granted to Amgen Europe on May 29, 2019 following the initial filing on Mar 20, 2003 under the application number EP10162667A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUMar 2, 2020ADMISSIBLE
HEXALFeb 28, 2020ADMISSIBLE
HOFFMANN EITLEFeb 28, 2020ADMISSIBLE
ZENTIVA KSFeb 28, 2020ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBFeb 26, 2020ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents